Precision Oncology Investments Continue Amid Stubborn Operational Difficulties, Survey Shows
Premium
Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times for advanced therapies.
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeating the disease.
Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, researchers said.
The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.